Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Gain Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Alder Matthias (CEO) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Exercised 825 restricted stock units
@ $0 |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Alder Matthias (CEO) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Exercised 3,300 restricted stock units
@ $0 |
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/23/2023 |
8-K
| Quarterly results |
| 12/21/2022 |
3
| Fuggetta Gianluca (Principal Accounting Officer) has filed a Form 3 on Gain Therapeutics, Inc. |
| 12/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/22/2022 |
4
| RICHMAN ERIC I (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 329,400 options to buy
@ $3.5, valued at
$1.2M
Granted 54,900 restricted stock units
@ $0 |
|
| 09/22/2022 |
4
| Islam Khalid (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 10,500 options to buy
@ $3.5, valued at
$36.8k
|
|
| 09/22/2022 |
4
| Riley Jeffrey Scott (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 10,500 options to buy
@ $3.5, valued at
$36.8k
|
|
| 09/22/2022 |
4
| GOLDSTEIN DOV A MD (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 10,500 options to buy
@ $3.5, valued at
$36.8k
|
|
| 09/22/2022 |
4
| Melincoff Gwen A (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 10,500 options to buy
@ $3.5, valued at
$36.8k
|
|
| 09/22/2022 |
4
| Nicaise Claude (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 10,500 options to buy
@ $3.5, valued at
$36.8k
|
|
| 09/22/2022 |
4
| HASLER HANS PETER (Director) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 10,500 options to buy
@ $3.5, valued at
$36.8k
|
|
| 09/22/2022 |
4
| Alder Matthias (COO) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Granted 60,900 options to buy
@ $3.5, valued at
$213.2k
Granted 10,200 restricted stock units
@ $0 |
|
| 09/20/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Transition Agreement, by and between the Company and Eric Richman",
"AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement is effective as of , by and between Gain Therapeutics, Inc. and Matthias Alder . This Agreement amends, restates, and supersedes in its entirety the Employment Agreement between the Company and Executive entered into effective October 15, 2021 . WHEREAS, the Company desires to continue to retain the services of Executive, now in the role of Chief Executive Officer as further set forth in this Agreement; WHEREAS, the Company’s Board of Directors desires to appoint Executive as the Company’s President and Chief Executive Officer as further set forth in this Agreement, effective as of the Effective Date; and WHEREAS, Executive desires to serve the Company in such capacity, subject to the terms and conditi...",
"GAIN THERAPEUTICS Announces PROMOTION OF Matthias Alder TO chief executive officer" |
|
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/15/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/17/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/27/2022 |
4
| RICHMAN ERIC I (CEO) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Bought 2,482 shares
@ $2.58, valued at
$6.4k
|
|
| 05/23/2022 |
4
| RICHMAN ERIC I (CEO) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Bought 4,000 shares
@ $2.71, valued at
$10.8k
Bought 9,256 shares
@ $2.83, valued at
$26.2k
|
|
| 05/23/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 05/23/2022 |
4/A
| Calabrese Salvatore (CFO) has filed a Form 4 on Gain Therapeutics, Inc.|
Txns:
| Bought 3,000 shares
@ $2.7, valued at
$8.1k
|
|
|
|
|